Johnson & Johnson (JNJ)'s Dividend Legacy: How a Healthcare Giant Built a Record of Consistent Dividends

Johnson & Johnson (NYSE:JNJ) is included among the 13 Best Consistent Dividend Stocks to Buy Now.

Johnson & Johnson (NYSE:JNJ) is an American multinational pharmaceutical, biotech, and medical technologies company. It has a highly diversified business with a wide range of medicines in its pharmaceutical division. Key growth drivers include cancer treatments Darzalex and Erleada, along with Remicade, which is used for various immunology conditions. The company has also introduced new products, such as Imaavy for myasthenia gravis, which received approval earlier this year, and it is awaiting regulatory feedback on TAR-200, a promising investigational treatment for bladder cancer.

In addition, Johnson & Johnson (NYSE:JNJ) is a major player in the medical device sector. A potential long-term growth opportunity lies in its robotic-assisted surgery system, Ottava, which is currently in clinical trials in the US.

Johnson & Johnson (NYSE:JNJ) is popular among income investors as the company is a Dividend King with 63 years of dividend growth. The company currently pays a quarterly dividend of $1.30 per share and has a dividend yield of 2.92%, as of September 12.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Dividend Stocks to Buy for Retirement and 10 Best Strong Buy Dividend Stocks to Invest in Now.

Disclosure: None.